Not Yet Recruiting
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
NCT07703436
- Conditions
- Astrocytoma IDH Mutant Grade 2, Astrocytoma IDH Mutant Grade 3, Glioma, +12 more
- Locations
-
Not specified